核黄素四丁酸酯(Riboflavin Butyrate) - 在研适应症：高胆固醇血症，核黄素缺乏_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Riboflavin 2',3',4',5'-tetrabutyrate、Riboflavin Tetabutyrate、Riboflavin butyrate (JP17)

+ [6]

靶点-

作用方式-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

高胆固醇血症核黄素缺乏

非在研适应症-

原研机构

Mitsubishi Tanabe Pharma Corp.

在研机构

Nipro ES Pharma KK

成都利尔药业有限公司

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1979-09-28),

高胆固醇血症核黄素缺乏

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C33H44N4O10

InChIKeyMJNIWUJSIGSWKK-BBANNHEPSA-N

CAS号752-56-7

关联

29

项与核黄素四丁酸酯相关的临床试验

NCT06100952

/ Active, not recruiting临床3期

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus (APRICITY-B)

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

开始日期2023-11-01

申办/合作机构

Epion Therapeutics, Inc.

NCT06100939

/ Active, not recruiting临床3期

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-A)

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

开始日期2023-10-30

申办/合作机构

Epion Therapeutics, Inc.

NCT05027295

/ Recruiting临床3期

A Randomized Study to Evaluate the Safety and Efficacy of Corneal Collagen Crosslinking Performed With Continuous vs Pulsed UVA Light for Reducing Corneal Curvature in Eyes With Keratoconus and Post-refractive Corneal Ectasia

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies.
Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

开始日期2021-07-30

申办/合作机构-

100 项与核黄素四丁酸酯相关的临床结果

登录后查看更多信息

100 项与核黄素四丁酸酯相关的转化医学

登录后查看更多信息

100 项与核黄素四丁酸酯相关的专利（医药）

登录后查看更多信息

211

项与核黄素四丁酸酯相关的文献（医药）

2023-04-01·International Journal of Food Science & Technology

Nanoemulsions loaded with compound photosensitisers: synergistic photodynamic inactivation effects of curcumin and riboflavin tetra butyrate

作者: Zhuang, Hong ; Yuan, Yuan ; Fang, Qiangsheng ; Zhang, Yushu ; Li, Rui ; Zhang, Chunling

SummaryAntimicrobial photodynamic therapy (aPDT) is an effective method in the field of sterilisation. Singlet oxygen (1O2) is an important substance in photodynamic sterilisation that needs to be detected. It involves energy transfer from an excited photosensitiser to surrounding oxygen molecules to produce cytotoxic 1O2 species, a process termed as type II reaction. Traditional photodynamic sterilisation for fresh produce generally involves only a single photosensitiser and uses nanoemulsions coating to make the photosensitiser work better. This allows the emulsion to produce only a limited amount of reactive oxygen species (ROS) in the presence of light, such that the bactericidal effect is limited. We have innovatively compounded two photosensitisers and stored them as nanoemulsions. The composite photosensitiser produces relatively higher ROS and the nanoemulsions have good stability as well as rheological properties, and the photosensitisers are well coated in the emulsions. In summary, nanoemulsions based on composite photosensitisers showed synergistic activity in controlling the growth of Staphylococcus aureus, which provides a novel approach for raw sterilisation to maintain food safety.

2023-01-18·Chemistry – A European Journal

Multistimuli‐Responsive Chromism of Vinylene‐Linked Bisflavin Based on the Aggregation and Redox Properties

Article

作者: Okamoto, Koyo ; Li, Zimeng ; Kawamorita, Soichiro ; Naota, Takeshi

AbstractMultistimuli‐responsive chromism was observed for vinylene‐linked bisflavin 1 a with an extended π‐conjugated platform. The yellow emission of a dilute solution of 1 a in CHCl3 (0.2 mM) observed at 298 K under UV excitation was changed to orange or red emission upon (1) an increase of concentration, (2) a decrease of temperature, and (3) variation of the solvent. This is in contrast to the almost non stimuli‐responsive chromism of the N‐methylated bisflavin analogue 1 b and monoflavin 2 a. Mechanistic investigation by 1H NMR analysis under various conditions revealed that the extended π‐conjugation platform and imide moiety of 1 a generate controllability in the formation of lower‐ and higher‐ordered aggregates, which induce variation of the emission color upon change. Bisflavin 1 a also exhibited redox‐induced chromism, where the orange emission of 1 a was quenched by the addition of hydrazine under anaerobic conditions, and changed back to the original emission upon subsequent bubbling of O2 gas.

2022-08-16·ACS Macro Letters

Versatile Method of Generating Triboluminescence in Polymer Films Blended with Common Luminophores

Article

作者: Khusnutdinova, Julia R. ; Fayzullin, Robert R. ; Karimata, Ayumu

Herein we report a versatile method for the preparation of triboluminescent polymer films by physical blending with common luminophores. This method does not require the presence of a crystalline phase or the use of materials known to be triboluminescent. Emission is generated in response to friction of the polymer surface via triboelectrification, either by rubbing directly or through an inert coating layer, even with low applied stress (<0.1 MPa). Our findings offer a convenient and practical method of preparation of triboluminescent, amorphous polymer films with easily tunable emission properties.

100 项与核黄素四丁酸酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01913	-	S01XA26	DB14727

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高胆固醇血症	日本	Nipro ES Pharma KK	1979-09-28
核黄素缺乏	日本	Nipro ES Pharma KK	1979-09-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00674661 (CXL, CTgov)	临床3期	角膜扩张	130	UVA Irradiation+riboflavin ophthalmic solution (Corneal Collagen Cross-linking (CXL) Treatment Group)	鏇構艱製繭醖艱艱夢遞(觸廠艱鹽壓繭窪範積蓋) = 網廠壓醖鏇鹹構艱顧膚艱觸淵願顧窪夢願蓋製 (衊範夢觸鬱遞窪艱膚構, 願構範鏇築鏇壓窪簾築 ~ 蓋簾網齋廠觸窪簾鏇願) 更多	-	2017-01-27
				riboflavin ophthalmic solution (Control Group)	鏇構艱製繭醖艱艱夢遞(觸廠艱鹽壓繭窪範積蓋) = 願積範壓範淵網積壓構艱觸淵願顧窪夢願蓋製 (衊範夢觸鬱遞窪艱膚構, 鹹夢鹽齋齋簾構鹹糧範 ~ 艱襯餘廠鑰夢膚糧餘齋) 更多
NCT00647699 (CXL, CTgov)	临床3期	圆锥角膜	147	UVA Irradiation+riboflavin ophthalmic solution (Corneal Collagen Cross-linking (CXL) Treatment Group)	選衊鹽餘鑰夢壓衊簾餘(顧鬱夢繭獵觸鹹艱襯構) = 獵憲醖鏇襯憲糧鹽製襯餘鹽窪壓築襯艱觸積願 (憲醖廠鹹衊遞鹹鑰選淵, 觸餘艱築選廠築鹹構鏇 ~ 膚膚鏇鑰壓鏇窪製築淵) 更多	-	2016-07-07
				riboflavin ophthalmic solution (Control Group)	選衊鹽餘鑰夢壓衊簾餘(顧鬱夢繭獵觸鹹艱襯構) = 糧廠艱觸積鏇襯顧憲鑰餘鹽窪壓築襯艱觸積願 (憲醖廠鹹衊遞鹹鑰選淵, 醖鏇憲鹽窪憲醖觸願糧 ~ 襯艱鑰範觸製鏇獵築襯) 更多
NCT01190306 (CTgov)	临床3期	圆锥角膜	127	The VEGA UV-A Illumination System+Riboflavin (CXL Treatment)	製艱齋鬱廠壓鹹顧餘齋(淵餘醖襯築蓋糧夢夢餘) = 繭製窪鬱顧製築憲糧餘觸糧簾窪範餘選齋願網 (簾觸鑰醖鬱鹹蓋衊淵範, 糧遞積醖鹽繭遞鑰鑰鹽 ~ 願築網膚醖鏇築顧選製) 更多	-	2013-03-04
				Riboflavin (Sham Control)	製艱齋鬱廠壓鹹顧餘齋(淵餘醖襯築蓋糧夢夢餘) = 鑰選鏇觸鏇繭鬱淵網獵觸糧簾窪範餘選齋願網 (簾觸鑰醖鬱鹹蓋衊淵範, 獵築鏇網構壓鹽憲獵齋 ~ 窪襯繭糧築窪衊願襯繭) 更多
NCT01398839 (CTgov)	临床3期	-	103	VEGA UV-A Illumination System+Riboflavin (CXL Treatment)	簾襯蓋築積獵網鹹淵積(鏇鹹壓顧鬱襯襯網鹽膚) = 獵鹽鹹製鹹願餘鬱醖醖選願蓋鹹簾積觸膚選蓋 (鏇壓襯顧顧醖選範壓鬱, 選窪願窪夢獵衊觸壓鏇 ~ 淵鬱襯窪膚憲窪窪繭窪) 更多	-	2013-03-04
				Riboflavin (Sham Control)	簾襯蓋築積獵網鹹淵積(鏇鹹壓顧鬱襯襯網鹽膚) = 齋鑰襯襯網構獵願壓簾選願蓋鹹簾積觸膚選蓋 (鏇壓襯顧顧醖選範壓鬱, 顧壓襯網艱淵壓憲壓襯 ~ 簾壓鹹鹹簾淵醖鬱糧鹹) 更多